# Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN)

> **NCT03258359** · PHASE1 · UNKNOWN · sponsor: **PersImmune, Inc** · enrollment: 12 (estimated)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** PACTN

## Key facts

- **NCT ID:** NCT03258359
- **Lead sponsor:** PersImmune, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-01
- **Primary completion:** 2020-12-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2020-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03258359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03258359, "Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03258359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*